African Intellectual Property Organization (OAPI): These 2 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in African Intellectual Property Organization (OAPI)

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "African Intellectual Property Organization (OAPI): These 2 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

When can OMONTYS (peginesatide acetate) generic drug versions launch?

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: African Intellectual Property Organization (OAPI) Patent 13,164
Patent Title: Novel peptides that bind to the erythropoietin receptor.

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

When can VYZULTA (latanoprostene bunod) generic drug versions launch?

Generic name: latanoprostene bunod
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: African Intellectual Property Organization (OAPI) Patent 13,356
Patent Title: Prostaglandin nitrooxyderivatives.

VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.